论文部分内容阅读
作者观察了重组人α-干扰素(α-2b:Intron A,美国先灵葆雅药厂出品)治疗慢性乙型肝炎的抗病毒疗效。治疗组26例慢性乙型肝炎病人每次接受α-干扰素3百万单位,每周3次连续12周,对照组25例慢性乙型肝炎病人不接受α-干扰素治疗。所有病人至少随访6个月。结果显示,治疗组病人HBeAg、DNAP和HBV-DNA的转阴率分别为42.9％、52.2％和37.5％,对照组病人分别为9.1％、15％和4.5％,前者明显高于后者(P<0.05)。在治疗组,慢性活动性肝炎(CAH)HBeAg、DNAP和HBV-DNA转阴率分
The authors looked at the antiviral efficacy of recombinant human interferon alpha (α-2b: Intron A, manufactured by Schering-Pley Pharmaceuticals, USA) in the treatment of chronic hepatitis B. In the treatment group, 26 patients with chronic hepatitis B received 3 million interferon alpha each time for 3 times a week for 12 weeks, and 25 patients with chronic hepatitis B in the control group did not receive interferon-alpha. All patients were followed up for at least 6 months. The results showed that the negative conversion rates of HBeAg, DNAP and HBV-DNA were 42.9%, 52.2% and 37.5% in the treatment group and 9.1%, 15% and 4.5% in the control group respectively, the former was significantly higher than the latter <0.05). In the treatment group, chronic active hepatitis (CAH) HBeAg, DNAP and HBV-DNA negative rate